Table 2.
Summary findings of treatment comparisons.
| Endpoint post-burn | Treatment group | Body weight/motor control | H3/p-Raf (drug response biomarkers) | c-fos+ | Dendritic spine dysgenesisa | Pain threshold | Iba1/GFAP | Rac1/Pak1 |
|---|---|---|---|---|---|---|---|---|
| Day 6 | Burn + DMSO | ∅ | ↑ | ↓ | ↓* | ↑* | * | ∅ |
| Burn + anti-Pak1 | ||||||||
| Day 10 (drugwithdrawn) | Burn + DMSO | ∅ | * | * | * | |||
| Burn + anti-Pak1 | ||||||||
| Sham | Control | |||||||
Note: Dendritic spine dysgenesis outcome measures include changes in density and distribution. Pain threshold measures include behavioral assessments for tactile allodynia and heat hyperalgesia. DMSO: dimethyl sulfoxide; ∅: no significant change in any tests; ↑↓: significant up/down change following anti-Pak1 treatment; *: significant difference from Sham control values.
a
Defined as different from Sham control values.